Biotech News

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

Y-mAbs (YMAB)Y-mAbs2025-08-07 11:30 ESTEarnings

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will

Related news

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

REGNRegeneron Pharmaceuticals2026-07-30 10:30 EST

Regeneron Reports Second Quarter 2026 Financial and Operating Results

GERNGeron2026-07-22 11:00 EST

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

IMCRImmunocore Holdings plc2026-07-30 11:00 EST

Immunocore to report second quarter 2026 financial results and host call on August 6, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

View all latest news

Y-mAbs

Y-mAbs Therapeutics is an oncology and rare-disease company focused on antibody-based therapies. Its platform has been built around highly specific biologic treatments for difficult diseases.

Recent company news

YMABY-mAbs2025-09-16 12:41 EST

SERB Pharmaceuticals Completes Acquisition of Y-mAbs Therapeutics

YMABY-mAbs2025-08-08 10:35 EST

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

YMABY-mAbs2025-08-07 11:30 EST

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

YMABY-mAbs2025-08-05 12:30 EST

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

YMABY-mAbs2025-05-28 10:35 EST

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States